We, Kewpie Corporation, have developed an innovative hyaluronic acid specially designed for knee osteoarthritis, Hyabest®(J). For this product, we obtained 8-week clinical data based on WOMAC randomized double-blind placebo-controlled clinical trial.
Attached herewith, please find out related exhibits .

Hyabest®(J) [336KB]

We did one survey in Japan based on JKOM ( Japanese Knee Osteoarthritis Measurement – Japanse equivalent of WOMAC),and came by satisfactory result as attached (see-Exhibit 1). However, the survey was done for the Japanese, and was not double-blind placebo-controlled, therefore we later did another one in USA ,more authentic worldly known one, WOMAC.

As has been stipulated in the report, Hyabest®(J), both in case of 200mg/day dosage and 100mg/day dosage, proved to contribute to significant improvement in all scores of WOMAC (see-Exhibit 2).
It is the fact, however , that result of placebo was also good especially during 1st half (0-4 weeks). For this, please refer to N Engl J Med 354:8, 795-794, 2006, in which you may notice how placebo tends to produce good result.
Furthermore, we did an exploratory analysis for the subgroup (moderate-to-severe conditioned subjects) (see-Exhibit 3), from which you may understand how our Hyabest®(J) ,both 200mg and 100mg were effective for the group of people.

Our advisory doctor is explaining the mechanism of how Hyabest®(J) alleviates joint pain (see-Exhibit 4). He also made a noteworthy trial how Hyabest®(J) could retard advancement of osteoarthritis (see-Exhibit 5).